Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

by Apgar, Charles , Verghese, Philip B. , Rabinovici, Gil D. , Whitmer, Rachel A. , Eastwood, Stephanie , Wente‐Roth, Traci L. , Holtzman, David M. , Meyer, Matthew R. , Verbel, David , Irvin, Faith , Yarasheski, Kevin E. , Sachdev, Pallavi , Venkatesh, Venky , Fogelman, Ilana , Monane, Mark , West, Tim , Contois, John , Braunstein, Joel B. , Kirmess, Kristopher M. , Holubasch, Mary S. , Bateman, Randall J. , Hanna, Lucy , Siegel, Barry A. , Irizarry, Michael , Ito, Satoshi

in Aged / Aged, 80 and over / Agreements / Algorithms / Alzheimer Disease - blood / Alzheimer Disease - diagnosis / Alzheimer Disease - diagnostic imaging / Alzheimer's / Alzheimer's disease / amyloid beta / Amyloid beta-Peptides - blood / Biological markers / Biomarkers / Biomarkers - blood / Blood / blood biomarker / Blood tests / Brain / Brain - diagnostic imaging / Brain - metabolism / Brain research / Chromatography / clinical validity / Dementia / diagnostic / Diagnostic tests / Disease / Enrollments / Ethnicity / FDA approval / Female / Humans / Male / Mass Spectrometry / Medical diagnosis / Middle Aged / Mild cognitive impairment / Neuroimaging / Pathology / Peptide Fragments - blood / Peptides / Plasma / Positron emission tomography / Positron emission tomography (PET) / p‐tau217 / ROC Curve / Scientific imaging / Spectrometry / tau Proteins - blood / Test validity and reliability / Tomography

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

2024

Confirm

Do you wish to request the book?

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Apgar, Charles,

Verghese, Philip B.,

Rabinovici, Gil D.,

Whitmer, Rachel A.,

Eastwood, Stephanie,

Wente‐Roth, Traci L.,

Holtzman, David M.,

Meyer, Matthew R.,

Verbel, David,

Irvin, Faith,

Yarasheski, Kevin E.,

Sachdev, Pallavi,

Venkatesh, Venky,

Fogelman, Ilana,

Monane, Mark,

West, Tim,

Contois, John,

Braunstein, Joel B.,

Kirmess, Kristopher M.,

Holubasch, Mary S.,

Bateman, Randall J.,

Hanna, Lucy,

Siegel, Barry A.,

Irizarry, Michael,

Ito, Satoshi

2024

Overview

BACKGROUND With the availability of disease‐modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment. METHODS High‐throughput, mass spectrometry‐based assays were used to measure %p‐tau217 and amyloid beta (Aβ)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers to identify brain amyloidosis by PET. RESULTS The area under the receiver operating characteristic curve (AUC‐ROC) for %p‐tau217 (0.94) was statistically significantly higher than that for p‐tau217 concentration (0.91). The AUC‐ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2, was 0.94, yielding 88% agreement with amyloid PET. Diagnostic performance of the APS2 was similar by ethnicity, sex, age, and apoE4 status. DISCUSSION The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.

Share this book

Add to My Shelf

Publisher

John Wiley & Sons, Inc,John Wiley and Sons Inc

Subject

/ Alzheimer Disease - blood

/ Alzheimer Disease - diagnosis

/ Alzheimer Disease - diagnostic imaging